Cingulate publishes phase 3 ADHD drug trial results in peer-reviewed journal
Tweet Send to a Friend
Cingulate Inc. (NASDAQ: CING) announced that Phase 3 clinical trial results for its lead drug candidate, CTx-1301 (dexmethylphenidate HCl), have ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
